Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG-011 nasal spray in adults with moderate-to-severe seasonal allergic rhinitis
CTR20250489Phase 3Completed
- Sponsor
- Puqi Pharma
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing PG-011 nasal spray with Placebo nasal spray (2 arms). Primary endpoint: Change from baseline in average reflective total nasal symptom score during 14 days of treatment. Started Feb 2025; status: completed.
02
Drugs
pumecitinib
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20250489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250489.